CYP27B1 and non-small cell lung carcinoma: Studies using this approach have led to the discovery of clinically relevant phenotype-genotype correlations, such as CYP2D6 polymorphisms and tamoxifen activity on important clinical endpoints [29], polymorphisms in SLCO1B1 and irinotecan pharmacokinetics and toxicity correlation [30], DPD variants and fluorouracil toxicity correlation [31], or CYP27B1 and CYP24A1 polymorphisms and non small cell lung cancer risk [32].